NHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
National Health Investors Inc (NHI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators suggest a neutral to bearish trend, and while there are positive catalysts such as the company's strategic focus on private-pay senior housing and debt repayment, the financial performance shows declining net income and EPS. Analysts' ratings are mixed, with some optimism about future occupancy improvements. However, the lack of strong proprietary trading signals and no significant positive momentum in the stock price makes it prudent to hold rather than buy right now.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 21.79. Moving averages are converging, suggesting indecision in the market. The stock is trading near its support level of 77.635, with resistance at 81.876. Overall, the technical outlook is neutral to bearish.
NHI's focus on private-pay senior housing and allocating 70% of 2026 investments to its SHOP platform.
Debt repayment plans from the $560 million healthcare property sale.
Analysts expect occupancy improvements in the senior housing operating portfolio.
Declining net income (-11.80% YoY) and EPS (-15.79% YoY) in Q4
Gross margin dropped by 10.35% YoY.
No significant hedge fund or insider trading trends.
Bearish technical indicators and weak short-term price trend.
In Q4 2025, revenue increased by 23.40% YoY to $105.8M, but net income dropped by 11.80% YoY to $38.1M. EPS decreased by 15.79% to $0.8, and gross margin fell to 75.43%, down 10.35% YoY. While revenue growth is a positive, declining profitability metrics are concerning.
Analysts are mixed. Truist raised the price target to $92 with a Buy rating, citing favorable fundamentals and expected occupancy improvements. Wells Fargo raised the price target to $86 but maintained an Equal Weight rating, noting potential overestimation of the FFO impact from rent resets.
